MetaCap

Cryo-Cell International Inc. (CCEL)

NYSE: CCELHealth CareMisc Health and Biotechnology ServicesUSD

4.150.00 (0.00%)

At close: Nov 20, 3:55 PM ET · Delayed 15 min

CCEL stock chart

Technical analysis

Key statistics

All statistics
Market cap
$33.46M
EPS (TTM)
-$0.24
Ex-dividend date
May 21, 2025
52-week range
2.72 – 5.45
Day range
4.15 – 4.20
Volume / Avg
2.64K / 13.02K
Beta
—

52-week range

$2.72$5.45

CCEL stock today

Cryo-Cell International (CCEL) closed at $4.15 on Nov 20, essentially unchanged from the prior close, versus the S&P 500's 3.70% decline. Trading was light, with 2.64K shares changing hands, about 20% of the average daily volume. Shares are 23.9% below their 52-week high of $5.45, set on Oct 29, 2026 and 52.6% above the 52-week low of $2.72, in the middle of the past year's range.

CCEL is up 20.6% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 1.5%. Cryo-Cell International has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Cryo-Cell International

Company profile

Cryo-Cell International, Inc. engages in cord blood and cord tissue cryopreservation services in the United States. The company offers cellular processing and cryogenic storage for family use, primarily for collection and preservation of umbilical cord blood, and tissue stem cells; and cellular processing and cryogenic storage of umbilical cord blood stem cells for public use.

Industry
Misc Health and Biotechnology Services
CEO
Mr. David I. Portnoy
Headquarters
Oldsmar, FL
Employees
72
IPO year
2022

Financial highlights

Full financials

In fiscal 2025, Cryo-Cell International generated $31.6 million in revenue, down 1.3% from fiscal 2024, its first annual decline since 2021. Cryo-Cell International reported a net loss of $2.4 million, compared with net income of $402,095 a year earlier. Gross margin was 76.6% (up from 75.2%) and operating margin 1.5%.

Cryo-Cell International annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$31.57M$31.99M$31.34M$30.34M$28.88M
Growth-1.31%+2.05%+3.32%+5.03%-7.26%
Net income$-2.43M$402.10K$-9.52M$2.77M$2.08M
EPS (diluted)$-0.30$0.05$-1.14$0.33$0.25

Earnings

Earnings history
Last reported (Aug/2026)
Oct 9, 2026
EPS actual vs est.
$0.16 vs —

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$0.15
Ex-dividend date
May 21, 2025

CCEL news

All CCEL news

Cryo-Cell International peers

Health Care sector
CCEL peer companies
CompanyPrice% ChgMarket capCompare
MGRXMangoceuticals Inc.0.1236-7.55%$2.75Mvs CCEL
NIVFNewGenIvf Group Limited Class A0.0269-23.14%$80.77Kvs CCEL
PARKPark Dental Partners Inc.17.03-6.79%$94.26Mvs CCEL
VMDViemed Healthcare Inc.8.52-1.05%$322.85Mvs CCEL
AGLagilon health inc.90.24+0.83%$1.52Bvs CCEL
PGNYProgyny Inc.35.71+0.73%$2.63Bvs CCEL
SHCSotera Health Company15.91-1.85%$4.54Bvs CCEL
DVADaVita Inc.161.03+3.00%$10.13Bvs CCEL

Indexes, lists and sector

Cryo-Cell International stock FAQ

What is Cryo-Cell International's stock price today?

CCEL last traded at $4.15 as of Nov 20, 3:55 PM EST, up 0.00% on the day. Prices are delayed at least 15 minutes.

Does Cryo-Cell International pay a dividend?

Yes. Cryo-Cell International pays $0.00 per share annually. The most recent dividend of $0.15 had an ex-dividend date of May 21, 2025.

Who is Cryo-Cell International's CEO?

Mr. David I. Portnoy is the chief executive officer of Cryo-Cell International Inc., which has about 72 employees.

What is the CCEL 52-week high?

The 52-week high for CCEL is $5.45 and the 52-week low is $2.72. The stock is currently 23.9% below its high.

Compare CCEL